BioReliance Corporation Launches a Validated Assay to Detect Calicivirus 2117 in Biological Samples  
10/6/2009 8:12:49 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--BioReliance Corporation announced today that it has launched a fully validated assay which can sensitively detect the presence of Calicivirus 2117 in biological samples. The test is designed to provide manufacturers of biological therapeutics and other biologically based products the ability to detect this potential contaminant of mammalian cell culture based systems. Calicivirus 2117 (also referred to as Vesivirus 2117) was recently described as the causative agent in the shutdown of a major biotechnology manufacturing facility.